Phone: 86-02585560000-1588

這個頁面上的內容需要較新版本的 Adobe Flash Player。

取得 Adobe Flash Player

About us / 公司简介
Nanjing KCI Biotech (KCI) is a preclinical Contract Research Organization (CRO) providing specialty preclinical pharmacology services in cardiovascular diseases, immune diseases, inflammatory diseases, metabolic diseases and renal diseases. The core competency of KCI stems from our pioneering work and expertise in developing and running specialized animal disease models to test drug candidates and medical devices for their pharmacological effects and biocompatible repairs. We also conduct adjacency studies in PK/PD, preliminary toxicology and pathology. Overall, we provide one-stop shopping of preclinical pharmacology services for early proof of concept of therapeutics and fulfillment of regulatory requirements.
Partners / 应用案例
  • 1
  • 2
  • 3
News / 新闻动态
Nanjing/P.R. China and Singapore, December 15th, 2014 InvitroCueand Nanjing KCI Biotech have signed an agreement to establish a strategic partnership with the aim to provide image analysis services for preclinical drug testing. KCI is a preclinical contract research organization (CRO) with core competency in developing and running specialized animal disease models for drug testing and medical device testing. KCI has chosen InvitroCue, a specialist in digital pathology, as its exclusive service partner for image-based analysis. In addition, both companies will collaborate to develop new tools and validateInvitroCue’s existing image processing applications. “We are pleased to have entered this agreement with Nanjing KCI Biotech. It allows us to leverage on KCI’s expertise in preclinical research and specialized animal disease models. It also helps InvitroCue to extend its presence in China and to promote digital pathology”, said Dr Steven Fang, Founder and CEO of InvitroCue. “The partner...
2013 - 12 - 11
Nanjing/P.R. China and Singapore, December 15th, 2014 InvitroCueand Nanjing KCI Biotech have signed an agreement to establish a strategic partnership with the aim to provide image analysis services for preclinical drug testing. KCI is a preclinical contract research organization (CRO) with core competency in developing and running specialized animal disease models for drug testing and medical device testing. KCI has chosen InvitroCue, a specialist in digital pathology, as its exclusive service partner for image-based analysis. In addition, both companies will collaborate to develop new tools and validateInvitroCue’s existing image processing applications. “We are pleased to have entered this agreement with Nanjing KCI Biotech. It allows us to leverage on KCI’s expertise in preclinical research and specialized animal disease models. It also helps InvitroCue to extend its presence in China and to promote digital pathology”, said Dr Steven Fang, Founder and CEO of InvitroCue. “The partner...
2013 - 12 - 11
Contact Us

Nanjing KCI Biotech Inc.

Address:699-18 XuanWu Avenue Nanjing,Jiangsu,China

Phone:86-025-85560000-1588


86-02585560000-1588

Copyright ©2005 - 2013 Nanjing KCI Biotech Inc.
进入手机网站